DNTH – dianthus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $40.00 price target on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $33.00 to $38.00. They now have an "outperform" rating on the stock.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Form 424B3 Dianthus Therapeutics,
Form 10-Q Dianthus Therapeutics, For: Mar 31
Form 8-K Dianthus Therapeutics, For: May 09
Form ARS Dianthus Therapeutics, For: Dec 31
Form DEFA14A Dianthus Therapeutics,
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.